These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 39024509)
1. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway. Zhang Y; Zhang T; Chen L; Guo Z; Jiang X Aging (Albany NY); 2024 Jun; 16(14):11208-11223. PubMed ID: 39024509 [TBL] [Abstract][Full Text] [Related]
2. miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway. Wang L; Tang B; Han H; Mao D; Chen J; Zeng Y; Xiong M Cancer Biother Radiopharm; 2018 Feb; 33(1):32-38. PubMed ID: 29412697 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781 [TBL] [Abstract][Full Text] [Related]
4. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition. Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667 [TBL] [Abstract][Full Text] [Related]
5. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway. Zheng J; Liu C; Shi J; Wen K; Wang X Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077 [TBL] [Abstract][Full Text] [Related]
6. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway. Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526 [TBL] [Abstract][Full Text] [Related]
7. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway. Liu B; Xu L; Dai EN; Tian JX; Li JM Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30442873 [TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308 [TBL] [Abstract][Full Text] [Related]
9. Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. Aoki Y; Kubota Y; Masaki N; Obara K; Tome Y; Bouvet M; Nishida K; Hoffman RM Anticancer Res; 2024 Jul; 44(7):2787-2792. PubMed ID: 38925854 [TBL] [Abstract][Full Text] [Related]
10. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Sun H; Yin M; Qian W; Yin H Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951 [TBL] [Abstract][Full Text] [Related]
11. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway. Li H; Shen X; Ma M; Liu W; Yang W; Wang P; Cai Z; Mi R; Lu Y; Zhuang J; Jiang Y; Song Y; Wu Y; Shen H J Exp Clin Cancer Res; 2021 Oct; 40(1):340. PubMed ID: 34706747 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene. Li KW; Wang SH; Wei X; Hou YZ; Li ZH Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012 [TBL] [Abstract][Full Text] [Related]
13. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway. Jin R; Jin YY; Tang YL; Yang HJ; Zhou XQ; Lei Z Oncol Rep; 2018 Jun; 39(6):3034-3040. PubMed ID: 29620278 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma. Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383 [TBL] [Abstract][Full Text] [Related]
15. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells. Yang J; Zou Y; Jiang D Int J Mol Med; 2018 Apr; 41(4):1845-1854. PubMed ID: 29393336 [TBL] [Abstract][Full Text] [Related]
16. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis. Zhao GS; Gao ZR; Zhang Q; Tang XF; Lv YF; Zhang ZS; Zhang Y; Tan QL; Peng DB; Jiang DM; Guo QN J Exp Clin Cancer Res; 2018 Aug; 37(1):188. PubMed ID: 30092789 [TBL] [Abstract][Full Text] [Related]
17. HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway. Li X; Huang Q; Wang S; Huang Z; Yu F; Lin J Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):345-362. PubMed ID: 32181480 [TBL] [Abstract][Full Text] [Related]
18. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. Zhang Y; Cheng H; Li W; Wu H; Yang Y Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524 [TBL] [Abstract][Full Text] [Related]
19. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. Wang Q; Liu MJ; Bu J; Deng JL; Jiang BY; Jiang LD; He XJ Life Sci; 2021 Mar; 268():118925. PubMed ID: 33358903 [TBL] [Abstract][Full Text] [Related]
20. Tizanidine hydrochloride exhibits a cytotoxic effect on osteosarcoma cells through the PI3K/AKT signaling pathway. Xing XW; Sun YF; Zhao J; Pan ZX; Jiang WX J Int Med Res; 2019 Aug; 47(8):3792-3802. PubMed ID: 31179788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]